Susana Banerjee

Trials

Studies that name Susana Banerjee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07665515 · Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  Epitopea Ltd · recruiting · Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer · principal investigator
• Ph3
  NCT06072781 · A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  Verastem, Inc. · recruiting · Low Grade Serous Ovarian Cancer · principal investigator
• Ph2
  NCT05990192 · SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

  Institute of Cancer Research, United Kingdom · recruiting · Ovarian Cancer Recurrent · principal investigator
• Ph1
  NCT05226507 · A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

  Nuvectis Pharma, Inc. · terminated · Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma · principal investigator
• Ph2
  NCT04625270 · A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

  Verastem, Inc. · active not recruiting · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer · principal investigator
• N/A
  NCT04300699 · Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer

  Royal Marsden NHS Foundation Trust · unknown · Ovarian Cancer, Chemotherapy, Quality of Life · principal investigator
• N/A
  NCT04295577 · Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

  Royal Marsden NHS Foundation Trust · completed · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · study chair
• Ph2
  NCT04065269 · ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

  Institute of Cancer Research, United Kingdom · active not recruiting · Gynaecological Cancers · principal investigator
• Ph2
  NCT02659384 · Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

  European Organisation for Research and Treatment of Cancer - EORTC · completed · Ovarian Neoplasms · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.